Longevity & AgingFinerenone Slows Kidney Decline in CKD Patients Without Diabetes
Finerenone, a drug previously approved for kidney disease in type 2 diabetes, now shows meaningful kidney protection in people without diabetes too. The FIND-CKD trial followed over 1,500 adults with chronic kidney disease and found that finerenone slowed the annual loss of kidney filtration rate compared to placebo. It also reduced the combined risk of serious kidney or cardiovascular events by 23%. Importantly, it worked similarly whether or not patients were already taking SGLT2 inhibitors, a frontline kidney-protective drug class. Since more than half of CKD cases occur in non-diabetic individuals, this expands the potential pool of people who could benefit. Elevated potassium levels were the main side effect to monitor.
